Therapeutic drug monitoring: How to improve drug dosage and patient safety in tuberculosis treatment

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 101-104

  Sotgiu, Giovanni ^a   Alffenaar, Jan Willem C ^b   Centis, Rosella ^c   D'Ambrosio, Lia ^c   Spanevello, Antonio ^d,e   Piana, Andrea ^a   Migliori, Giovanni Battista ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d IRCCS   (Italy)

^e UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Drug dosage; MDR TB; Prevention; Therapeutic drug monitoring; Treatment; XDR TB

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; BLOOD SAMPLING; DRIED BLOOD SPOT TESTING; DRUG DOSE; DRUG MONITORING; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATIENT SAFETY; PROGNOSIS; BLOOD; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG MONITORING; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; PATIENT SAFETY; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84925234402     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.12.001     Document Type: Article

References (44)

1. Framework for tuberculosis elimination in low-incidence countries. WHO/HTM/TB/2014.13 2014, World Health Organization, World Health Organization, Geneva.
2. Sotgiu G., Mauch V., Migliori G.B., Benedetti A. Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. Eur Respir J 2014, 43:1563-1566.
3. Voniatis C., Migliori G.B., Voniatis M., Georgiou A., D'Ambrosio L., Centis R., et al. Tuberculosis elimination: dream or reality? The case of Cyprus. Eur Respir J 2014, 44:543-546.
4. Diel R., Loddenkemper R., Zellweger J.P., Sotgiu G., D'Ambrosio L., Centis R., et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013, 42:785-801.
5. D'Ambrosio L., Dara M., Tadolini M., Centis R., Sotgiu G., van der Werf M.J., et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014, 43:1410-1420.
6. Global tuberculosis report 2014. WHO/HTM/TB/2014.08 2014, World Health Organization, World Health Organization, Geneva.
7. Skrahina A., Hurevich H., Zalutskaya A., Sahalchyk E., Astrauko A., Van Gemert W., et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012, 39:1425-1431.
8. Migliori G.B., Dara M., De Colombani P., Kluge H., Raviglione M.C. Multidrug-resistant tuberculosis in Eastern Europe: still on the increase?. Eur Respir J 2012, 39:1290-1291.
9. Abubakar I., Zignol M., Falzon D., Raviglione M., Ditiu L., Masham S., et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013, 13:529-539.
10. Migliori G.B., De Iaco G., Besozzi G., Centis R., Cirillo D.M. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007, 12. E070517.1.
11. Udwadia Z., Vendoti D. Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining. J Epidemiol Community Health 2013, 67:471-472.
12. Migliori G.B., Centis R., D'Ambrosio L., Spanevello A., Borroni E., Cirillo D.M., et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease?. Clin Infect Dis 2012, 54:1379-1380.
13. Migliori G.B., Sotgiu G., Gandhi N.R., Falzon D., Deriemer K., Centis R., et al. The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013, 42:169-179.
14. Ahuja S.D., Ashkin D., Avendano M., Banerjee R., Bauer M., Bayona J.N., et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9:e1001300.
15. Falzon D., Gandhi N., Migliori G.B., Sotgiu G., Cox H., Holtz T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013, 42:156-168.
16. Falzon D., Jaramillo E., Schünemann H.J., Arentz M., Bauer M., Bayona J., et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
17. Floyd K., Hutubessy R., Kliiman K., Centis R., Khurieva N., Jakobowiak W., et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J 2012, 40:133-142.
18. Loddenkemper R., Sotgiu G., Mitnick C.D. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?. Eur Respir J 2012, 40:9-11.
19. Diel R., Rutz S., Castell S., Schaberg T. Tuberculosis: cost of illness in Germany. Eur Respir J 2012, 40:143-151.
20. Srivastava S., Pasipanodya J.G., Meek C., Leff R., Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011, 204:1951-1959.
21. Pasipanodya J.G., Srivastava S., Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012, 55:169-177.
22. Cegielski J.P., Dalton T., Yagui M., Wattanaamornkiet W., Volchenkov G.V., Via L.E., et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014, 59:1049-1063.
23. Heysell S.K., Moore J.L., Keller S.J., Houpt E.R. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010, 16:1546-1553.
24. Peloquin C.A. Pharmacological issues in the treatment of tuberculosis. Ann N Y Acad Sci 2001, 953:157-164.
25. Alsultan A., Peloquin C.A. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014, 74:839-854.
26. Pasipanodya J., Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011, 55:24-34.
27. Lange C., Abubakar I., Alffenaar J.W., Bothamley G., Caminero J.A., Carvalho A.C., et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014, 44:23-63.
28. Migliori G.B., Sotgiu G., D'Ambrosio L., Centis R., Lange C., Bothamley G., et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?. Eur Respir J 2012, 39:619-625.
29. Raviglione M.C., Lange C., Migliori G.B. Preventing and managing antimicrobial resistance: imperative for chest physicians. Eur Respir J 2011, 37:978-981.
30. Van der Werf M.J., Langendam M.W., Huitric E., Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 2012, 39:1511-1519.
31. Tortoli E., Russo C., Piersimoni C., Mazzola E., Dal Monte P., Pascarella M., et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012, 40:442-447.
32. Srivastava S., Peloquin C.A., Sotgiu G., Migliori G.B. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?. Eur Respir J 2013, 42:1449-1453.
33. Bolhuis M.S., van Altena R., van Soolingen D., de Lange W.C., Uges D.R., van der Werf T.S., et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013, 42:1614-1621.
34. Akkerman A.O., Van Altena R., Klinkenberg T., Brouwers A., Bongaerts A., Van der Werf T.S., et al. Drug concentration in lung tissue in multidrug resistant tuberculosis. Eur Respir J 2013, 42:1750-1752.
35. Kim H.J., Seo K.A., Kim H.M., Jeong E.S., Ghim J.L., Lee S.H., et al. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry. J Pharm Biomed Anal 2014, 102C:9-16.
36. Vu D.H., Alffenaar J.W., Edelbroek P.M., Brouwers J.R., Uges D.R. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des 2011, 17:2931-2939.
37. Vu D.H., Koster R.A., Alffenaar J.W., Brouwers J.R., Uges D.R. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:1063-1070.
38. Vu D.H., Bolhuis M.S., Koster R.A., Greijdanus B., de Lange W.C., van Altena R., et al. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012, 56:5758-5763.
39. Vu D.H., Koster R.A., Bolhuis M.S., Greijdanus B., Altena R.V., Nguyen D.H., et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. Talanta 2014, 121:9-17.
40. Li J., Burzynski J.N., Lee Y.A., Berg D., Driver C.R., Ridzon R., Munsiff S.S. Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest 2004, 126:1770-1776.
41. Peloquin CA. Therapeutic drug monitoring: assays and cost 2013. Personal communication; 2013.
42. Esposito S., Codecasa L., Centis R. TB elimination, individualised drug dosage and minimisation of adverse effects: the role of therapeutic drug monitoring (TDM). Eur Respir J 2014, in press.
43. International Standards for Tuberculosis Care (ISTC), diagnosis, treatment, public health 2014, TB CARE I, TB CARE I, The Hague, Netherlands. Edition 3.
44. Migliori G.B., Zellweger J.P., Abubakar I., Ibraim E., Caminero J.A., De Vries G., et al. European Union standards for tuberculosis care. Eur Respir J 2012, 39:807-819.